Barely Significant
← all phrases

“nominally significant”

7,733 sentences · 7,733 papers · 10,034 search hits before verification · confirmed specimen

Sighted at

p=0.08

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

[ 30 ] that analyzed the outcome with metformin in patients with non-alcoholic fatty liver disease (NAFLD) or steato-hepatitis (NASH) with COVID-19 without diabetes, has also shown a reduced risk of hospital admission in metformin users (36/6700) (OR 0.42; 95% CI, 0.18–1.01; p = 0.05) compared to the non-users, although it was nominally significant.
ETHOS used a Cox proportional hazard model adjusted for lung function and age, variables that were not used in the secondary Cox analysis in TORCH, which still showed a nominally significant difference, with a 19% reduction in risk ( 1 ).The ETHOS data suggest that a dose response of effectiveness may exist for mortality in a way not seen when exacerbations are the endpoint, with the number needed to treat for a mortality gain with 320 BFF being 80 patients per year.
[29] In the present study, less obvious air pollution effect variation by genotype was suggested for GSTP1 rs596603 and the GSTT1 null variant, where air pollution exposure was associated with a higher and nominally significant risk of AMI in subjects with GT or TT genotype in GSTP1 rs596603 vs GG (OR 2.12, 95% CI 1.09–4.10 vs OR 1.40, 95% CIs 0.73–2.68), as well as for individuals carrying the non-null genotype of GSTT1 , i.e. the presence of a coding gene, compared to subjects with the null genotype (OR 2.02, 95% CI 1.13–3.60 vs OR 1.40, 95% CI 0.33–5.96).
Although the study did not meet its primary endpoint (least-squares [LS] mean change in PANSS total score at Week 6: −14.3 vs −12.2 for placebo; LS mean difference −2.0, 95 % CI –4.5 to 0.5; p = 0.11), post hoc subgroup analyses revealed a nominally significant benefit among patients receiving non-risperidone background therapy (n ̃ 130), with a mean PANSS reduction of −15.1 for COBENFY versus −11.7 for placebo (LS mean difference −3.4; 95 % CI –6.3 to −0.5; p ≈ 0.03) [ 106 ].
Targeting muscarinic receptors for treating schizophrenia.
Neurotherapeutics · 2026 · PMC12976554
In the mild AD APOE4/4 group, the effect on the Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) was 5.4 points, and effects on the functional outcomes of the Clinical Dementia Rating—Sum of Boxes (CDR-SB) and the Disability Assessment for Dementia (DAD) were also nominally significant.
Analysis of MSigDB Hallmark gene sets further identified biologically pertinent, albeit nominally significant, coordinated changes: the epithelial–mesenchymal transition signature was positively enriched, whereas the DNA repair pathway was negatively enriched, suggesting a concomitant activation of tissue-remodeling programs and a potential decline in genomic maintenance ( Fig. 3 B).